| General Information of Drug Metabolite (DM) (ID: DM017146) |
| DM Name |
Tucatinib metabolite M23
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Oxidation - Oxidation |
Tucatinib
|
[1] |
|
Cytochrome P450 3A5 (CYP3A5)
|
DME0012
|
| Oxidation - Oxidation |
Tucatinib
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| Tucatinib |
DR5343
|
Approved |
HER2-positive breast cancer |
|
|
| References |
| 1 |
Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
